Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Breast cancer, metastatic

5383 - Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): results from the multicohort phase II FINESSE trial


21 Oct 2018


Poster Discussion session - Breast cancer, metastatic


Cytotoxic Therapy

Tumour Site

Breast Cancer


Rina Hui


Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272


R. Hui1, A. Pearson2, J. Cortes Castan3, C. Campbell4, C. Poirot5, H.A. Azim Jr.6, D. Fumagalli7, M. Lambertini8, F. Daly4, A. Arahmani7, J. Perez-Garcia9, P.G. Aftimos10, P. Bedard11, L. Xuereb5, S. Loibl12, S. Loi13, M. Pierrat5, N.C. Turner14, F. André15, G. Curigliano16

Author affiliations

  • 1 Department Of Medical Oncology, Westmead Hospital and the University of Sydney, 2145 - Sydney/AU
  • 2 The Breast Cancer Now Research Centre, The Institute of Cancer Research, London/GB
  • 3 Iob Institute Of Oncology, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 4 N/a, Frontier Science Scotland, Kingussie/GB
  • 5 N/a, Institut de Recherches Internationales Servier, Suresnes/FR
  • 6 Internal Medicine, American University of beirut, Beirut/LB
  • 7 Scientific Department, Breast International Group, 1000 - Brussels/BE
  • 8 Department Of Medecine, Institute Jules Bordet, 1000 - Brussels/BE
  • 9 Department Of Oncology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona/ES
  • 10 Medical Oncology, Institut Jules Bordet, 1000 - Brussels/BE
  • 11 Medical Oncology, Princess Margaret Cancer Centre, University Health Network, M5G2M9 - Toronto/CA
  • 12 Gbg, German Breast Group Forschungs GmbH, 63263 - Neu-Isenburg/DE
  • 13 Translational Breast Cancer Genomics Lab, Division Of Research, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 14 Toby Robins Breast Cancer Research Centre, Royal Marsden Hospital and Institute of Cancer Research, London/GB
  • 15 Breast Cancer Unit, Department Of Medical Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 16 Early Drug Development for Innovative Therapies Division, Istituto Europeo di Oncologia, 20141 - Milan/IT


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5383


Fibroblast growth factor receptor-1 (FGFR1) gene is amplified in about 15% of HR+ HER2- breast cancer (BC) pts. Lucitanib is an inhibitor of FGFR1 and VEGFR-1,2, and 3.


HR+ HER2- MBC pts received oral lucitanib in 3 centrally confirmed cohorts: 1) FGFR1 amplified, 2) FGFR1 non-amplified, 11q13 amplified, 3) FGFR1 and 11q13 non-amplified, until intolerable toxicity, disease progression or pt withdrawal. Main inclusion criteria included ECOG PS < 1, at least 1 line and no more than 2 lines of chemotherapy. Primary endpoint was ORR. The study used a Simońs 2-stage design: if > 2 pts responded among 21 pts, 20 additional pts could be enrolled in each cohort. FGFR1 copy number variations (CNV) were determined by FISH and ddPCR, while FGFR1 expression by IHC. Serum FGF23 was assessed by ELISA.


76 pts (32/18/26 in cohorts 1/2/3) from nine countries were enrolled. 92% of pts had received >1 lines of chemotherapy. The most frequent AEs were hypertension (76% grade >3), hypothyroidism (45%), nausea (33%) and proteinuria (32%). ORR were 19% (95%CI: 9-35%), 0% (0-17%), 15% (6-33%) in cohorts 1, 2, 3 respectively. Clinical benefit rates (CR, PR and SD > 24 weeks) were 41% (25.52 - 57.7), 11% (3.10 - 32.8), 27% (13.70 - 46.1) respectively. Exploratory biomarker analyses suggested that pts with high FGFR1 amplification (FGFR1/centromere ratio >4 , n = 16) presented higher ORR than those without high level amplification (n = 37) (25% versus 8%). ORR in pts with FGFR1-high tumors (IHC, H-score >50) was 25% (n = 5/20) while ORR was 8% in FGFR1-low cancers. The 20 patients with FGFR1 membrane over-expression had in average 3-month longer PFS (212[165-NA] days) than other patients (109[57-158] days). Serum FGF23 levels after 14 days of lucitanib were significantly increased from baseline (p < 0.0001), suggesting an effective targeting on FGFR.


While the study was stopped prematurely based on a decision by the sponsor in relation to efficacy and safety signals, the FINESSE trial suggests that lucitanib has antitumor activity in pts with HR+ HER2- MBC. Biomarker analyses generates the hypothesis that pts with high FGFR1 expression could derive more benefit. This population deserves further exploration in large trial.

Clinical trial identification

NCT02053636 Protocol no.: BIG 2-13/CL2-80881-001.

Legal entity responsible for the study

Breast International Group, Brussels, Belgium.



Editorial Acknowledgement


R. Hui: Advisory board member: Merck Sharp and Dohme, AstraZeneca, Novartis, Roche, Bristol-Myers Squibb; Honorarium: Merck Sharp and Dohme, AstraZeneca, Novartis, Roche. C. Poirot, L. Xuereb, M-J. Pierrat: Employee: Servier. H.A. Azim Jr.: Consultancy: Roche; Employment: Innate Pharma. D. Fumagalli, A. Arahmani, P. Bedard: Research funding for the trial to institution: Servier. P.G. Aftimos: Honoraria: Synthon, Boehringer Ingelheim, Macrogenics, Amgen, Novartis; Travel grants: Amgen, Merck, Roche. S. Loi: To institution: Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology and Pfizer; Consultant (not compensated): Seattle Genetics, Pfizer, Novartis, BMS, Merck, Roche- Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.